Cognitive Decline & Memory Loss Treatment
Most memory problems are either diagnosed too late or missed entirely. By the time a standard neurology workup flags a problem, years of treatable decline have already passed. We catch cognitive changes early, identify the metabolic and molecular drivers behind them, and treat the causes rather than wait for a diagnosis of dementia.
The Problem with Waiting
The standard approach to memory complaints in neurology follows a familiar pattern. The patient reports forgetfulness. The physician administers a brief screening tool like the Montreal Cognitive Assessment. If the score is above the cutoff for impairment, the patient is told that their memory is “within normal limits” and asked to come back in a year. If the score is borderline, a structural MRI is ordered. If the MRI shows no large-vessel strokes or mass lesions, the patient is reassured and sent home.
The problem is that by the time these standard tools detect a change, the underlying disease process has been running for a decade or more. Amyloid plaque deposition in Alzheimer’s disease begins fifteen to twenty years before the first clinical symptoms appear (Jack et al., 2013, The Lancet Neurology). Neuroinflammation and synaptic loss are well established before any screening questionnaire can pick them up. The window for meaningful intervention is not the moment of diagnosis. It is the years before that moment, when the brain is still compensating and the damage is still reversible.
Blood-based biomarkers have changed what is possible. Plasma p-tau217, a phosphorylated tau species, now identifies Alzheimer’s-related pathology with over 95% accuracy compared to PET and CSF standards (Palmqvist et al., 2020, JAMA). This means that clinicians no longer need to wait for a patient to fail a screening test or show atrophy on imaging. The molecular signature of disease is detectable in a blood draw years before clinical decline becomes obvious.
This is the principle behind what we call the Neuroeconomy: cognition is the primary unit of value in a human life. Every year of undetected decline carries a compounding cost—to career performance, to relationships, to independence, to the quality of the years that remain. Treating that decline as an inevitable part of aging, rather than as a measurable and modifiable biological process, is a choice. And it is the wrong one.
What a Precision Evaluation Reveals
Our evaluation begins with structural MRI to measure hippocampal volume, cortical thickness, and white matter integrity. Hippocampal atrophy is one of the earliest structural markers of Alzheimer’s disease and can be quantified years before clinical symptoms emerge. We also use PET scanning to map glucose metabolism across the brain. Regions of hypometabolism in the temporal and parietal lobes are characteristic of early neurodegenerative processes and often appear while the patient is still performing normally on office-based cognitive tests.
Blood-based biomarkers add a molecular layer to the structural and metabolic picture. We measure plasma p-tau217, which reflects tau phosphorylation specific to Alzheimer’s pathology. We also measure neurofilament light chain (NfL), a marker of axonal damage that rises in multiple neurodegenerative conditions. Homocysteine levels indicate methylation status and B-vitamin adequacy, both of which directly affect neuronal health. Brain-derived neurotrophic factor (BDNF) levels tell us about the brain’s capacity for synaptic maintenance and repair. Inflammatory markers including IL-6 and TNF-alpha help identify chronic neuroinflammation that accelerates neuronal loss.
Neurogenomic testing completes the evaluation. We look at genetic variants that affect amyloid clearance (APOE status), methylation pathways (MTHFR and related polymorphisms), detoxification capacity, and neurotransmitter metabolism. These results explain why a given patient is declining at the rate they are, and they inform which therapeutic targets are most likely to produce a measurable response.
The combination of imaging, blood biomarkers, and genomics produces a diagnostic picture that no single test provides alone. Learn more about our imaging capabilities on our brain imaging page.
Our Treatment Approach
Treatment protocols are assembled from several regenerative and metabolic therapies based on each patient’s diagnostic findings. No two protocols are identical because no two patients arrive with the same combination of drivers.
NAD+ IV Therapy
Nicotinamide adenine dinucleotide is the central coenzyme in mitochondrial energy production. Neurons with declining mitochondrial output produce less ATP and accumulate more oxidative damage. IV NAD+ restores the substrate these cells need to maintain metabolic function. Braidy et al. (2019, Antioxidants & Redox Signaling) showed that NAD+ depletion is a consistent feature of age-related neurodegeneration.
Exosome Therapy
Extracellular vesicles derived from mesenchymal stem cells cross the blood-brain barrier and deliver anti-inflammatory cytokines, neurotrophic factors, and regulatory microRNAs to damaged neural tissue. These vesicles modulate the local immune environment and support repair processes in regions where chronic inflammation is driving neuronal loss.
Stem Cell Therapy
Mesenchymal stem cells provide paracrine signaling that reduces neuroinflammation, supports angiogenesis, and promotes trophic factor release in areas of neurodegeneration. A phase I trial by Brody et al. (2023, Nature Medicine) found that intrathecal MSC administration in Alzheimer’s patients was safe and associated with reduced CSF biomarkers of inflammation.
Ketamine Therapy
Ketamine acts on NMDA receptors and upregulates BDNF expression, supporting synaptic plasticity in circuits affected by neurodegeneration. For patients whose cognitive decline is accompanied by treatment-resistant depression, anxiety, or chronic pain, ketamine infusions can produce measurable improvements in mood and function that create a better foundation for other therapies.
These therapies are delivered together during our Intensive Brain Health Program, a three-to-five-day protocol that combines diagnostics, physician review, and a full course of treatment in a single visit.
Who Should Be Evaluated
Cognitive decline does not begin at a diagnosis. It begins years earlier, in patterns that are measurable if you know where to look.
Early Memory Changes in Your 40s Through 60s
You have noticed that you lose words more often, that names take longer to retrieve, that you re-read paragraphs you used to absorb on the first pass. Your annual physical says everything is fine. These changes may be age-related and benign, or they may be the earliest measurable signal of a process that will accelerate if left unaddressed. Biomarker testing can distinguish between the two.
Family History of Dementia
A first-degree relative with Alzheimer’s disease or another form of dementia increases your own risk by a factor of two to four, depending on the specific genetic and environmental overlap. APOE genotyping, p-tau217 levels, and metabolic imaging can establish your current risk profile and identify modifiable factors before symptoms appear.
Post-Concussion Cognitive Changes
Traumatic brain injury accelerates neurodegenerative pathology. Patients with a history of concussion or repetitive subconcussive exposure often develop cognitive symptoms in their 40s and 50s that would not have appeared until decades later in the absence of injury. Our TBI evaluation overlaps with our cognitive decline workup because the mechanisms are closely related.
Executives & Professionals with Declining Performance
You built a career on the speed and precision of your thinking, and you have noticed that both are slipping. Decisions take longer. Complex problems that you once worked through quickly now require more effort. These changes are not always pathological, but they are always worth measuring. For ongoing cognitive maintenance between clinic visits, we recommend Action Potential Supplements, our targeted supplementation line for brain health.
Related Treatments
Traumatic Brain Injury
TBI and cognitive decline share overlapping mechanisms. Prior head injury accelerates neurodegeneration through chronic neuroinflammation and mitochondrial dysfunction that standard imaging rarely detects.
NAD+ IV Therapy
Restore mitochondrial energy production in neurons with declining metabolic output. NAD+ is the primary substrate for ATP synthesis and a key regulator of sirtuins and DNA repair enzymes involved in neuroprotection.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals, growth factors, and regulatory microRNAs to regions where neuroinflammation is driving progressive neuronal loss.
Frequently Asked Questions
When should I worry about memory loss?+
What diagnostic tools do you use to evaluate cognitive decline?+
How is this different from what a standard neurologist would do?+
What treatments are available for cognitive decline?+
How long does the evaluation and treatment program take?+
Can cognitive decline actually be reversed?+
Your Brain Deserves a Real Evaluation
If your memory is changing and no one has measured why, that gap between what you’re experiencing and what your doctors have tested is exactly where we work. Dr. Orr and the team at The Neurogenesis Project are accepting new patients in St. Marys, Georgia.